Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bevan

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1S Bevan, T Pal, C R Greenberg, et al.
British Journal of Cancer|November 28, 2002
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumoursN Sodha, S Bullock, R Taylor, et al.
British Journal of Cancer|August 15, 2002
Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomasK T Barker, S Bevan, R Wang, et al.
British Journal of Cancer|May 18, 2001
CDX2 mutations do not account for juvenile polyposis or Peutz-Jeghers syndrome and occur infrequently in sporadic colorectal cancersK L Woodford-Richens, S Halford, A Rowan, et al.
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
Current Oncology (Toronto, Ont.)|April 29, 2016
Accrual of adolescents and young adults with cancer to clinical trialsA E Hay, C Rae, G A Fraser, et al.
Clinical Science (London, England : 1979)|February 3, 2006
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at termDavid O Bates, Philip P MacMillan, Joseph G Manjaly, et al.
Investigative Ophthalmology & Visual Science|March 19, 2010
VEGF-A165b is cytoprotective and antiangiogenic in the retinaAnette L Magnussen, Emma S Rennel, Jing Hua, et al.
British Journal of Cancer|March 20, 2008
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyA H R Varey, E S Rennel, Y Qiu, et al.
British Journal of Pharmacology|February 28, 2001
Pharmacological differences between the human and rat vanilloid receptor 1 (VR1)P McIntyre, L M McLatchie, A Chambers, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1S Bevan, T Pal, C R Greenberg, et al.
British Journal of Cancer|November 28, 2002
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumoursN Sodha, S Bullock, R Taylor, et al.
British Journal of Cancer|August 15, 2002
Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomasK T Barker, S Bevan, R Wang, et al.
British Journal of Cancer|May 18, 2001
CDX2 mutations do not account for juvenile polyposis or Peutz-Jeghers syndrome and occur infrequently in sporadic colorectal cancersK L Woodford-Richens, S Halford, A Rowan, et al.
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
Current Oncology (Toronto, Ont.)|April 29, 2016
Accrual of adolescents and young adults with cancer to clinical trialsA E Hay, C Rae, G A Fraser, et al.
Clinical Science (London, England : 1979)|February 3, 2006
The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at termDavid O Bates, Philip P MacMillan, Joseph G Manjaly, et al.
Investigative Ophthalmology & Visual Science|March 19, 2010
VEGF-A165b is cytoprotective and antiangiogenic in the retinaAnette L Magnussen, Emma S Rennel, Jing Hua, et al.
British Journal of Cancer|March 20, 2008
VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapyA H R Varey, E S Rennel, Y Qiu, et al.
British Journal of Pharmacology|February 28, 2001
Pharmacological differences between the human and rat vanilloid receptor 1 (VR1)P McIntyre, L M McLatchie, A Chambers, et al.
Pageof 24